Dopaminergic agonists in the treatment of Parkinson's disease.
Dopaminergic agonists are drugs that directly stimulate the dopamine receptors of the striatum and have proved useful in treating Parkinson's disease. In the United States, they are primarily used in conjunction with levodopa. Most have long half-lives and have been particularly useful in controlling and attempting to prevent motor fluctuations.
Goetz
C G
CG
Department of Neurological Sciences, Rush-Presbyterian-St. Luke's Medical Center, Chicago, Illinois.
Diederich
N J
NJ
D001058:Apomorphine / Q000627:therapeutic use; D001971:Bromocriptine / Q000627:therapeutic use; D015259:Dopamine Agents / Q000627:therapeutic use*; D006801:Humans; D007785:Lactose / Q000031:analogs & derivatives / Q000627:therapeutic use; D008090:Lisuride / Q000627:therapeutic use; D008747:Methylcellulose / Q000031:analogs & derivatives / Q000627:therapeutic use; D010078:Oxazines / Q000627:therapeutic use; D010300:Parkinson Disease / Q000188:drug therapy*; D010479:Pergolide / Q000627:therapeutic use; D011954:Receptors, Dopamine / Q000187:drug effects
D015259:Dopamine Agents; D010078:Oxazines; D011954:Receptors, Dopamine; C042631:naxagolide; D010479:Pergolide; D001971:Bromocriptine; D008747:Methylcellulose; C071191:MK 458; D008090:Lisuride; D007785:Lactose; D001058:Apomorphine